- Conditions
- Congestive Heart Failure, Hypotension
- Interventions
- True Acupuncture, Sham Acupuncture
- Procedure
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypotension, Orthostatic
- Interventions
- Treatment Phase 1, Treatment Phase 2, Treatment Phase 3
- Other · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy Volunteers
- Interventions
- Placebo, Fludrocortisone, Eplerenone
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Years to 9 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
- Conditions
- Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- ACE-232 tablets
- Drug
- Lead sponsor
- Acerand Therapeutics (Hong Kong) Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more
- Conditions
- Septic Shock
- Interventions
- Hydrocortisone
- Drug
- Lead sponsor
- University of Tennessee Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Healthy
- Interventions
- Opevesostat, Prednisone, Fludrocortisone acetate, Itraconazole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 55 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- ODM-208, Midazolam
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Interventions
- Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 63
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
- Conditions
- Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography
- Interventions
- Midodrine Hydrochloride
- Drug
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Healthy
- Interventions
- Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 48
- States / cities
- Orange, California • Palo Alto, California • Riverside, California + 41 more
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Abiraterone acetate
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Syncope, Vasovagal, Neurally-Mediated
- Interventions
- fludrocortisone acetate
- Drug
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Nashville, Tennessee • Richmond, Virginia
- Conditions
- Orthostatic Hypotension, Falls
- Interventions
- Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate, Dexamethasone, Prednisone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • Miami, Florida + 4 more
- Conditions
- Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
- Interventions
- MK-5684, Prednisone, Fludrocortisone acetate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Chicago, Illinois
- Conditions
- Hepatic Impairment, Healthy Participants
- Interventions
- Opevesostat, Prednisone, Fludrocortisone acetate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • San Antonio, Texas
- Conditions
- Advanced Metastatic Castration Resistant Prostate Cancer
- Interventions
- INV-9956
- Drug
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more
- Conditions
- Hearing Loss, Sensorineural
- Interventions
- Fludrocortisone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Malignant Neoplasm
- Interventions
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more